Considering that FST is not only elevated in the sera but also within the tumors of lung cancer patients, it is conceivable that the release of FST by CAFs forms a protective barrier around tumor cells, making them less responsive to TGF-β signals and ultimately promoting cell survival despite therapeutic pressures. The gene discussed is FST; the disease is neoplasm.